Selank was developed in Russia by the Institute of Molecular Genetics as an analog of tuftsin, a natural peptide from a region of the antibody immunoglobulin G
doi:10.1038/s41598-020-74022-y Lozic M, Stambolija V, Krezic I, et al
BPC 157 for Healing: Tissue Repair and Recovery Benefits Research demonstrates BPC-157s capacity to accelerate healing across multiple tissue types
A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the RILOMET-2 trial
Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials